Refills is a digital weight-care platform designed to make access to prescription GLP-1 treatment more convenient. The program connects eligible patients with licensed clinicians through an online intake and consultation process, with treatment options including semaglutide and tirzepatide. If a clinician determines that treatment is appropriate, the prescription can be coordinated with a U.S. pharmacy and delivered to the patient's home.
Several features are designed to make prescription weight management easier to manage.
● Online intake: The initial assessment can be completed remotely.
● Licensed clinician review: Treatment decisions are made by qualified healthcare professionals rather than through an automated questionnaire alone.
● Semaglutide and tirzepatide options: Eligible patients may be considered for either medication based on clinical judgment.
● Flat medication pricing: The program advertises the same base price regardless of dosage changes, helping make costs more predictable.
● No monthly membership or app fees: The program does not advertise separate monthly membership or app charges.
● Home delivery: Prescriptions can be shipped directly to the patient's home.
● Ongoing support: Patients can contact the care team about questions involving treatment, side effects, dosage, and refills.
● Month-to-month structure: The program does not require a long-term contract, allowing patients to cancel rather than being locked into a lengthy commitment.
Refills is an online weight-management service focused on prescription GLP-1 medications. Instead of requiring patients to begin the process through a traditional in-person weight-loss clinic, Refills allows eligible adults to complete an online health assessment and proceed through a clinician-guided prescription process remotely.
The program currently offers access to semaglutide and tirzepatide, depending on medical eligibility and clinician judgment.
An important distinction is that Refills is not simply an online store selling weight-loss medication. Prescription treatment requires clinical review, and the prescribing decision is made by a licensed healthcare professional.
For people who value convenience, privacy, and predictable pricing, this model can make the process of exploring prescription weight management considerably simpler.
The process is designed around three basic stages.
1. Complete an Online Health Assessment
The first step is completing a secure health intake questionnaire. Patients provide information about their health history, weight-management goals, current medications, and other factors that may affect treatment eligibility.
Providing accurate information is important because GLP-1 medications are prescription treatments and are not appropriate for everyone.
2. Receive Clinical Review
A licensed clinician reviews the information submitted during the intake. Depending on the patient's circumstances, additional communication or a telehealth consultation may be required.
The clinician determines whether a GLP-1 medication is medically appropriate and, if so, which treatment and dosage strategy is suitable.
3. Prescription, Pharmacy Fulfillment and Refills
If treatment is prescribed, the prescription is coordinated with a partner pharmacy. Medication can then be shipped to the patient's home.
Refills also form part of the ongoing process. Patients complete the necessary refill information and can communicate with the care team about questions involving treatment, progress, side effects, or dosage.
This creates a continuing care process rather than treating the initial prescription as the end of the experience.
The main potential advantage of Refills is convenience.
Traditional weight-management care may involve scheduling appointments, traveling to a clinic, waiting for appointments, and separately arranging prescription fulfillment. A digital model can combine much of this workflow into one process.
Another benefit is pricing transparency. Weight-loss treatment can become expensive when medication, consultations, membership charges, and other fees are billed separately. Refills uses a bundled pricing approach that includes medication access, provider consultations, and ongoing support.
The program may also appeal to people who prefer privacy. Receiving treatment from home can eliminate some of the discomfort associated with discussing weight-related concerns in a physical clinic.
Perhaps most importantly, Refills combines medication access with clinician oversight. That matters because GLP-1 medications can produce side effects and may require gradual dose adjustments.
Semaglutide is a GLP-1 receptor agonist that can help regulate appetite and food intake. It works partly by mimicking the activity of the naturally occurring hormone GLP-1, which influences appetite, digestion, and glucose regulation.
Clinical research has demonstrated significant weight-loss effects with once-weekly semaglutide when combined with lifestyle intervention. In the STEP 1 clinical trial, adults with overweight or obesity receiving 2.4 mg of semaglutide experienced an average weight reduction of 14.9% after 68 weeks, compared with 2.4% with placebo.
Tirzepatide is a newer medication that activates both GIP and GLP-1 pathways. This dual mechanism makes it different from semaglutide and has produced substantial weight-loss results in clinical trials.
In the SURMOUNT-1 trial, average weight reduction after 72 weeks ranged from 15.0% with the 5 mg dose to 20.9% with the 15 mg dose, compared with 3.1% with placebo.
Which medication is appropriate depends on individual medical circumstances. Patients should not select a dose simply because a particular dosage produced strong results for someone else.
The popularity of GLP-1 medications is supported by substantial clinical research.
Semaglutide has been evaluated in large randomized controlled trials. In the STEP 1 study, 1,961 adults with overweight or obesity were followed for 68 weeks. Semaglutide combined with lifestyle intervention produced substantially greater weight loss than placebo.
Tirzepatide has also undergone large randomized trials. In SURMOUNT-1, more than 2,500 adults with obesity or overweight plus a weight-related condition were treated for 72 weeks. The highest studied dose produced an average reduction of approximately 20.9% under the trial's treatment-regimen analysis.
Longer-term research has continued to show meaningful effects. A three-year analysis of tirzepatide in people with obesity and prediabetes found sustained weight reduction and a substantially lower risk of progression to type 2 diabetes compared with placebo.
These studies demonstrate that GLP-1-based medications can be powerful tools for weight management. However, results from clinical trials should never be interpreted as a guarantee that an individual patient will lose a specific amount of weight.
Refills is different from a traditional diet program because medication is central to the treatment model.
Lifestyle-only programs rely primarily on nutrition, exercise, sleep, and behavior modification. They remain important regardless of whether medication is used.
Traditional weight-loss clinics may provide in-person physician appointments, nutritional counseling, laboratory testing, and prescription medications. The major difference is that Refills emphasizes a remote, digital workflow.
Commercial diet programs may focus on meal plans, calorie tracking, coaching, or packaged foods rather than prescription medication.
GLP-1 treatment through conventional healthcare can provide access to FDA-approved medications but may involve insurance requirements, office visits, prior authorization, or higher out-of-pocket costs.
Refills can therefore be viewed as a convenient telehealth-based option rather than a replacement for healthy eating, physical activity, or comprehensive medical care.
Yes. Refills provides access to prescription GLP-1 treatment through licensed clinician review. A prescription is required.
The online intake can be started without insurance. Treatment remains subject to clinical approval and the applicable payment terms.
The program is structured on a month-to-month basis and does not require a long-term contract.
Timing depends on clinical review, prescription approval, pharmacy processing, and shipping. Delivery information is provided once the prescription is processed.
No. Individual results vary considerably. Clinical trial averages can provide useful context, but they cannot predict an individual's outcome.
No. Compounded medications are not FDA-approved and have not undergone the same FDA premarket review for safety, effectiveness, and quality as approved medications.
Explore personalized GLP-1 treatment options with online clinician support, convenient home delivery, and ongoing care.
Disclaimer: The information on this website is provided for general informational purposes only and should not be considered medical advice or a substitute for consultation with a qualified healthcare professional. Prescription weight-loss medications, including semaglutide and tirzepatide, should only be used under appropriate medical supervision. Individual results may vary based on factors such as medical history, starting weight, lifestyle, treatment plan, medication, dosage, and individual response. Consult a qualified healthcare professional to determine whether prescription weight-loss treatment may be appropriate for you.
This website contains affiliate links, and we may earn a commission if you make a purchase through our links, at no additional cost to you.